Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2019Therapeutic Advances in Medical OncologyOpen Access

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC

View Full Paper
Ask AI
Bookmark
Share

Authors

MCM. CinauseroIstituto Nazionale di Fisica Nucleare, Sezione di PadovaNLNoemi LaproviteraAzienda USL di BolognaGMGiovanna De MaglioUniversity of Udine

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cinausero et al. (2019) studied this question.

synapsesocial.com/papers/6a0f27eaa00258d2006c9ceehttps://doi.org/10.1177/1758835919885540
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Human Splicing Finder: an online bioinformatics tool to predict splicing signals2009 · 2,600 citations
  2. 2Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors2013 · 1,254 citations
  3. 3Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy2014 · 2,364 citations
  4. 4GenVisR: Genomic Visualizations in R2016 · 363 citations
  5. 5HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway2004 · 126 citations